Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Linagliptin safe and effective for African American patients with type 2 diabetes

Linagliptin safe and effective for African American patients with type 2 diabetes

Severity of nocturnal hypoxemia and SDB independently predict both T2DM and HbA1c levels

Severity of nocturnal hypoxemia and SDB independently predict both T2DM and HbA1c levels

Narrower CRAE may increase risk of CVD among African Americans with type 1 diabetes

Narrower CRAE may increase risk of CVD among African Americans with type 1 diabetes

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion announces results from LATUDA open-label study for schizophrenia

Plans to tackle growing waistlines and the obesity epidemic from the Institute of Medicine

Plans to tackle growing waistlines and the obesity epidemic from the Institute of Medicine

Current anticoagulant therapy to prevent stroke might not be sufficient for older women with AF

Current anticoagulant therapy to prevent stroke might not be sufficient for older women with AF

Call for cookery lessons in schools to reduce childhood obesity

Call for cookery lessons in schools to reduce childhood obesity

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Diabetes alone may cost a sixth of total NHS budget by 2035: Report

Diabetes alone may cost a sixth of total NHS budget by 2035: Report

Depomed, Valeant file suit against Watson over generic Glumetza

Depomed, Valeant file suit against Watson over generic Glumetza

Researchers identify risks in pregnancy related specifically to obesity

Researchers identify risks in pregnancy related specifically to obesity

Blood test to diagnose depression in adolescents

Blood test to diagnose depression in adolescents

Research supports link between alcohol consumption and type II diabetes

Research supports link between alcohol consumption and type II diabetes

Mylan receives FDA approval for generic Seroquel ANDA

Mylan receives FDA approval for generic Seroquel ANDA

Medtronic Resolute DES found effective through two years

Medtronic Resolute DES found effective through two years

Study validates Mitofusin 2 as possible target for treatment of diabetes mellitus

Study validates Mitofusin 2 as possible target for treatment of diabetes mellitus

Men with type 2 diabetes more likely to develop major cardiovascular events

Men with type 2 diabetes more likely to develop major cardiovascular events

Deficiency of Mitofusin 2 protein leads to insulin resistance, glucose intolerance

Deficiency of Mitofusin 2 protein leads to insulin resistance, glucose intolerance

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.